Related Experiment Video
Updated: Jul 21, 2025
Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
TIME Is Ticking for Cervical Cancer.
Vijay Kumar1, Caitlin Bauer1, John H Stewart1,2
1Department of Interdisciplinary Oncology, Stanley S. Scott Cancer Center, School of Medicine, Louisiana State University Health Science Center (LSUHSC), 1700 Tulane Avenue, New Orleans, LA 70012, USA.
Cervical cancer (CC) incidence is rising despite HPV vaccination. Understanding the tumor immune microenvironment (TIME) is crucial for developing effective immunotherapies against HPV-driven CC.
Area of Science:
- Oncology
- Immunology
- Gynecology
Background:
- Cervical cancer (CC) poses a significant global health burden, particularly for reproductive-age women.
- Human papillomavirus (HPV) is the primary etiological agent, but lifestyle factors also contribute to CC development.
- Despite HPV vaccination, CC incidence continues to rise, highlighting the need for novel therapeutic strategies.
Purpose of the Study:
- To elucidate the immune landscape of the normal cervix and its interaction with HPV infection.
- To analyze the alterations in immune cell populations within the cervical cancer tumor immune microenvironment (TIME).
- To explore the potential of targeting immune cells in the TIME for future CC therapeutic interventions.
Main Methods:
- Review of existing literature on cervical cancer immunology.
- Analysis of immune cell composition in normal cervical tissue and CC tumors.
- Discussion of immune cell functions and their roles in CC pathogenesis.
Main Results:
- The normal cervical immune environment plays a role in managing HPV infection.
- CC TIME is characterized by specific alterations in various immune cell types.
- These immune cell alterations present potential targets for immunotherapeutic approaches.
Conclusions:
- A comprehensive understanding of CC TIME is essential for advancing treatment options.
- Targeting specific immune cells within the TIME offers promising avenues for novel CC immunotherapies.
- Further research into immune cell-based strategies is warranted to combat rising CC incidence.
More Related Videos
10:26RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
Published on: March 11, 2014
13:41Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:34Inhibition of Cdk Activity
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
02:37DNA Damage Can Stall the Cell Cycle
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...